TG Therapeutics, Inc. (TGTX) Stock

TG Therapeutics, Inc. (TGTX) is a Healthcare stock trading at $56.50 (as of 2026-07-24), with a market capitalization of $8.65B and a trailing P/E of 19.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

TG Therapeutics, Inc. is a biopharmaceutical company that acquires, develops, and commercializes therapies, with a focus on B-cell malignancies and autoimmune diseases. Its pipeline includes ublituximab, umbralisib, cosibelimab, and other preclinical or licensed programs, targeting conditions such as B-cell non-Hodgkin lymphoma, CLL, multiple sclerosis, and related disorders.

Understand TG Therapeutics, Inc.: how it makes money

TG Therapeutics commercializes biopharmaceutical treatments for B-cell malignancies and autoimmune diseases, and it makes money primarily from net product revenue for B-cell therapies such as Briumvi in the U.S., plus potential licensing-related revenue.

The profit model is structurally driven by recurring U.S. net product revenue from its commercial-stage B-cell therapy (Briumvi), with period-to-period results also influenced by the timing of licensing and other non-product revenue.

Revenue by segment (latest quarter)
Briumvi US Net Product	$0.2B

Business quality (Strong): Clear focus on a commercial product (Briumvi) with an operating model supported by U.S. net product revenue, but segment and revenue-line details provided here are limited, so investors should watch leading demand indicators and the mix of product versus licensing timing.

Valuation: At 20× earnings, TGTX trades 16% above the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.

Bull case

Commercial revenue visibility in the U.S: Net product revenue is tracked explicitly for Briumvi in the U.S., and demand signals include new patient scripts and new prescribers.
High gross margin profile in the reported period: The latest quarter shows gross margin of 83.6%, suggesting product economics that can support operating profitability if sales scale.

Bear case

Concentration risk in its commercial product revenue stream: The provided operating metrics strongly center on Briumvi-related U.S. net product revenue, so performance may be sensitive to changes in adoption or payer dynamics.
Timing and classification effects can affect reported results: Reported revenue includes items such as pre-market net product revenue and upfront licensing fee revenue, which can introduce variability from quarter to quarter.

Valuation — source: SEC EDGAR (first-party)
Price	$56.50
Market Cap	$8.65B
P/E Ratio	19.5
EV / EBITDA	83.1
Price / Book	14.83
Price / Sales	13.76
FCF Yield	-1.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$616.29M
Net Margin	72.6%
Revenue Growth (YoY)	87.3%
EPS Growth (YoY)	1837.5%
FCF Growth (YoY)	-38.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	13.11 (safe)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	19.5
Sector P/E (Healthcare)	21.2
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-8.2%
vs Industry	14.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($739.24M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Michael S. Weiss
Employees	352
Country	US
IPO Date	2010-05-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-07-24.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.